Molecular mechanisms involved in chemoresistance in paediatric acute lymphoblastic leukaemia

Srpski Arhiv za Celokupno Lekarstvo

Volumn 136, Issue 3-4, 2008, Pages 187-192

  Stankovic, Tatjana ^a   Marston, Eliot ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

ALL; Chemoresistance; DNA damage response; Microarray

Indexed keywords

CHILD; DNA DAMAGE; DNA MICROARRAY; DRUG RESISTANCE; GENETICS; HUMAN; LYMPHATIC LEUKEMIA; REVIEW;

CHILD; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 52049110068     PISSN: 03708179     EISSN: None     Source Type: Journal    
DOI: 10.2298/SARH0804187S     Document Type: Review

References (60)

1. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339:605-615.
2. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14:18-24.
3. Chessells JM, Harrison CJ, Watson SL, Vora AJ, Richards SM. Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999. Br J Haematol 2002; 117:306-314.
4. Gaynon PS, Qu RP, Chappell RJ, et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse - the Children's Cancer Group Experience. Cancer 1998; 82:1387-1395.
5. Chessells JM, Veys P, Kempski H, et al. Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 123:396-405.
6. Klumper E, Pieters R, Veerman AJ, et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 1995; 86:3861-3868.
7. Langlands K, Craig JI, Anthony RS, Parker AC. Clonal selection in acute lymphoblastic leukaemia demonstrated by polymerase chain reaction analysis of immunoglobulin heavy chain and T-cell receptor delta chain rearrangements. Leukemia 1993; 7:1066-1070.
8. Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 2005; 131:579-587.
9. Casale F, D'Angelo V, Addeo R, et al. P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia. Oncol Rep 2004; 12:1201-1207.
10. De Moerloose B, Swerts K, Benoit Y, et al. The combined analysis of P-glycoprotein expression and activity predicts outcome in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 2003; 20:381-391.
11. den Boer ML, Pieters R, Kazemier KM, et al. Relationship between major vault protein/lung resistance protein, multidrug resistanceassociated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998; 91:2092-2098.
12. Volm M, Stammler G, Zintl F, Koomagi R, Sauerbrey A. Expression of lung resistance-related protein (LRP) in initial and relapsed childhood acute lymphoblastic leukemia. Anticancer Drugs 1997; 8:662-665.
13. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91:2001-2008.
14. Anderer G, Schrappe M, Brechlin AM, et al. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics 2000; 10:715-726.
15. Krajinovic M, Costea I, Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 2002; 359:1033-1034.
16. Michalak E, Villunger A, Erlacher M, Strasser A. Death squads enlisted by the tumour suppressor p53. Biochem Biophys Res Commun 2005; 331:786-798.
17. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10:26-35.
18. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281:1309-1312.
19. Zhao R, Gish K, Murphy M, et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 2000; 14:981-993.
20. Meek DW. The p53 response to DNA damage. DNA Repair (Amst) 2004; 3:1049-1056.
21. Sun Y. p53 and its downstream proteins as molecular targets of cancer. Mol Carcinog 2006; 45:409-415.
22. Peller S, Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat 2003; 21:277-284.
23. Wada M, Bartram CR, Nakamura H, et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 1993; 82:3163-3169.
24. Roman-Gomez J, Castillejo JA, Jimenez A, et al. 5' CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 2002; 99:2291-2296.
25. Campana D, Coustan-Smith E, Manabe A, et al. Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. Blood 1993; 81:1025-1031.
26. Pontvert-Delucq S, Hibner U, Vilmer E, et al. Heterogeneity of B lineage acute lymphoblastic leukemias (B-ALL) with regard to their in vitro spontaneous proliferation, growth factor response and BCL-2 expression. Leuk Lymphoma 1996; 21:267-280.
27. Hogarth LA, Hall AG. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 1999; 93:2671-2678.
28. Kaufmann SH, Karp JE, Svingen PA, et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998; 91:991-1000.
29. Lam V, Findley HW, Reed JC, Freedman MH, Goldenberg GJ. Comparison of DR5 and Fas expression levels relative to the chemosensitivity of acute lymphoblastic leukemia cell lines. Leuk Res 2002; 26:503-513.
30. Posovszky C, Friesen C, Herr I, Debatin KM. Chemotherapeutic drugs sensitize pre-B ALL cells for CD95- and cytotoxic T-lymphocyte-mediated apoptosis. Leukemia 1999; 13:400-409.
31. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 2004; 104:2492-2498.
32. Zhou M, Gu L, Findley HW, Jiang R, Woods WG. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res 2003; 63:6357-6362
33. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000; 14:399-402.
34. Perentesis JP, Bhatia S, Boyle E, et al. RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia 2004; 18:685-692.
35. Wiemels JL, Zhang Y, Chang J, et al. RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia. Leukemia 2005; 19:415-419.
36. Gustafsson B, Angelini S, Sander B, Christensson B, Hemminki K, Kumar R. Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. Leukemia 2005; 19:310-312.
37. Yokota S, Nakao M, Horiike S, et al. Mutational analysis of the N-ras gene in acute lymphoblastic leukemia: a study of 125 Japanese pediatric cases. Int J Hematol 1998; 67:379-387.
38. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004; 351:533-542.
39. Lugthart S, Cheok MH, den Boer ML, et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 2005; 7:375-386.
40. Holleman A, den Boer ML, de Menezes RX, et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 2006; 107:769-776.
41. Ploner C, Schmidt S, Presul E, et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance in acute lymphoblastic leukemia. J Steroid Biochem Mol Biol 2005; 93:153-160.
42. Staal FJ, van der Burg M, Wessels LF, et al. DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers. Leukemia 2003; 17:1324-1332.
43. Beesley AH, Cummings AJ, Freitas JR, et al. The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure. Br J Haematol 2005; 131:447-456.
44. Bhojwani D, Kang H, Moskowitz NP, et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 2006; 108:711-717.
45. Kirschner-Schwabe R, Lottaz C, Todling J, et al. Expression of late cell cycle genes and an increased proliferative capacity characterize very early relapse of childhood acute lymphoblastic leukemia. Clin Cancer Res 2006; 12:4553-4561.
46. Flotho C, Coustan-Smith E, Pei D, et al. A set of genes that regulate cell proliferation predict treatment outcome in childhood acute lymphoblastic leukemia. Blood 2007; 110:1271-1277.
47. Talby L, Chambost H, Roubaud MC, et al. The chemosensitivity to therapy of childhood early B acute lymphoblastic leukemia could be determined by the combined expression of CD34, SPI-B and BCR genes. Leuk Res 2006; 30:665-676.
48. Dunkler D, Michiels S, Schemper M. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer 2007; 43:745-751.
49. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005; 365:488-492.
50. Michiels S, Koscielny S, Hill C. Interpretation of microarray data in cancer. Br J Cancer 2007; 96:1155-1158.
51. The International Nijmegen Breakage Syndrome Study Group. Nijmegen breakage syndrome. Arch Dis Child 2000; 82:400-406.
52. Stankovic T, Kidd AM, Sutcliffe A, et al. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet 1998; 62:334-345.
53. Taylor AM, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia telangiectasia. Blood 1996; 87:423-438.
54. Gumy Pause F, Wacker P, Maillet P, Betts D, Sappino AP. ATM gene alterations in childhood acute lymphoblastic leukemias. Hum Mutat 2003; 21:554-562.
55. Liberzon E, Avigad S, Stark B, et al. Germ-line ATM gene alterations are associated with susceptibility to sporadic T-cell acute lymphoblastic leukemia in children. Genes Chromosomes Cancer 2004; 39:161-166.
56. Austen B, Powell J, Alvi A, et al. Mutations in the ATM gene lead to impaired survival of patients with B-CLL that is independent of IGVH mutation status Blood 2005; 106:3175-3182.
57. Austen B, Skowronska A, Baker C, et al. The mutation status of the residual ATM allele is a determinant of in vitro cellular responses, clone expansion and survival in CLL patients with chromosome 11q deletion. J Clin Onc 2007; 25:5448-5457.
58. Stankovic T, Stewart GS, Fegan C, et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 2002; 99:300-309.
59. Kurz EU, Lees-Miller SP. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst) 2004; 3:889-900.
60. Weston VJ, Austen B, Wei W, et al. Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-kappaB survival pathway signaling. Blood 2004; 104:1465-1473.